{
    "clinical_study": {
        "@rank": "107664", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Tobramycin Inhalation Powder (112 mg) once daily during 168 days"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140"
            }
        ], 
        "brief_summary": {
            "textblock": "To provide efficacy and safety data comparing two dosing schedules of Tobramycin Inhalation\n      Powder (TIP) for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic\n      fibrosis."
        }, 
        "brief_title": "Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Provide written informed consent, HIPPA (Health Insurance Portability and\n             Accountability Act) authorization (where applicable), and assent (as appropriate)\n             prior to the performance of any study-related procedure.\n\n          2. Confirmed diagnosis of CF\n\n          3. FEV1 at screening (Visit 1) \u226525% and \u2264 80% of normal predicted values for age, sex,\n             and height\n\n          4. P. aeruginosa must be present within 6 months prior to screening and at screening\n\n          5. Able to comply with all protocol requirements\n\n          6. Clinically stable in the opinion of the investigator\n\n        Exclusion Criteria:\n\n          1. History of Burkholderia cenocepacia (Bcc) complex within 2 years prior to screening\n             and/or Bcc complex at screening\n\n          2. Hemoptysis more than 60 cc at any time within 30 days prior to study drug\n             administration\n\n          3. History of hearing loss or chronic tinnitus deemed clinically significant by the\n             investigator\n\n          4. Serum creatinine 2 mg/dL or greater, BUN 40 mg/dL or greater, or an abnormal\n             urinalysis defined as 2+ or greater proteinuria at screening\n\n          5. Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics\n\n          6. Patients who are unable to discontinue previously received inhaled antibiotic\n             regimen(s) (inhaled antibiotics are not allowed other than study drug)\n\n          7. Use of inhaled aminoglycosides within 28 days prior to study drug administration\n             (Visit 2)\n\n          8. Use of systemic anti-pseudomonal antibiotics within 28 days prior to study drug\n             administration\n\n          9. Use of loop diuretics within 7 days prior to study drug administration\n\n         10. Administration of any investigational drug within 30 days prior to enrollment or 5\n             half-lives, whichever is longer\n\n         11. Signs and symptoms of acute pulmonary disease, e.g , pneumonia, pneumothorax\n\n         12. Hospitalization during the baseline visit\n\n         13. History of malignancy\n\n         14. Patients with clinically significant laboratory abnormalities (not associated with\n             the study indication) at screening\n\n         15. Patients with other clinically significant conditions (not associated with the study\n             indication) which might interfere with the assessment of this study\n\n         16. Patients or caregivers with a history of noncompliance to medical regimens and\n             patients or caregivers who are considered potentially unreliable\n\n         17. Pregnant or nursing (lactating) women\n\n         18. Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant, including women whose career, lifestyle, or sexual orientation\n             precludes intercourse with a male partner and women whose partners have been\n             sterilized by vasectomy or other means, UNLESS they are using two birth control\n             methods.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015663", 
            "org_study_id": "CTBM100CUS03"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1", 
                "Arm 2"
            ], 
            "description": "Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm", 
            "intervention_name": "Tobramycin Inhalation Powder", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tobramycin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cystic Fibrosis", 
            "CF"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36608-1128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724-5073"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92037"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90801"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033-4605"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95819"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ventura", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93003"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010-2120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32207"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pensacola", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32504"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glenview", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60025"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63104"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Orange", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07052"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87131-0001"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Hyde Park", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11040"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10595"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44308"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267-0564"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43606"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73112"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "92772"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033-8050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78723"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390-9151"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75708"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23219"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morgantown", 
                        "country": "United States", 
                        "state": "West Virginia", 
                        "zip": "26506"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Forced Expiratory Volume in 1 second (FEV1) percent predicted expresses FEV1 as a percentage of the \"predicted values\" for participants of similar characteristics (height, age, sex, and sometimes race and weight). A positive change from baseline in FEV1 percent predicted indicates improvement in lung function.", 
            "measure": "Change from baseline in Forced Expiratory Volume in 1 second ( FEV1) percent predicted", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Day 168"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015663"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Forced Expiratory Volume in 1 second (FEV1) percent predicted expresses FEV1 as a percentage of the \"predicted values\" for participants of similar characteristics (height, age, sex, and sometimes race and weight). A positive change from baseline in FEV1 percent predicted indicates improvement in lung function.", 
                "measure": "Percent change from baseline in Forced Expiratory Volume in 1 second (FEV1) percent predicted", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 168"
            }, 
            {
                "description": "Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC will be assessed via spirometry. A positive change from baseline in FVC indicates improvement in lung function.", 
                "measure": "Percent change from baseline in Forced Vital Capacity (FVC) percent predicted", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 168"
            }, 
            {
                "description": "The Forced Expiratory Flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry. A positive change from baseline in FEF indicates improvement in lung function. The predicted percent will be assessed.", 
                "measure": "Percent change from baseline in forced expiratory flow (FEF) 25%-75% predicted", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 168"
            }, 
            {
                "description": "Change from baseline in Pseudomonas aeruginosa sputum density will be measured by log10 colony forming units per gram of sputum.", 
                "measure": "Change from baseline in Pseudomonas aeruginosa sputum density", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 168"
            }, 
            {
                "description": "Time to the first hospitalization due to respiratory-related events (number of days) per patient.", 
                "measure": "Time to first hospitalization due to respiratory-related events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to day 168"
            }, 
            {
                "description": "Percentage of patients with hospitalization due to respiratory-related events", 
                "measure": "Percentage of patients with hospitalizations due to respiratory-related events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to day 168"
            }, 
            {
                "description": "The number of days in length of hospital stay per patient due to respiratory-related events will be measured.", 
                "measure": "Length of hospital stay due to respiratory-related events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to day 168"
            }, 
            {
                "description": "Time to first usage of anti-pseudomonal antibiotic per patient will be assessed by number of days", 
                "measure": "Time to first usage of anti-pseudomonal antibiotic", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to day 168"
            }, 
            {
                "description": "Percentage of patients who use anti-pseudomonal antibiotic will be assessed.", 
                "measure": "Percentage of patients who use anti-pseudomonal antibiotic", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to day 168"
            }, 
            {
                "description": "Number of days of use of anti-pseudomonal antibiotic per patient will be assessed.", 
                "measure": "Duration of use of anti-pseudomonal antibiotic", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to day 168"
            }, 
            {
                "description": "Change from baseline in tobramycin minimal inhibitory concentration for Pseudomonas aeruginosa will be measured by laboratory testing.", 
                "measure": "Change from baseline in tobramycin minimal inhibitory concentration for Pseudomonas aeruginosa", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and day 168"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}